FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012576274> ?p ?o ?g. }

• W3012576274 endingPage "1441" @default.
• W3012576274 startingPage "1428" @default.
• W3012576274 abstract "Osimertinib is a covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for treating non-small cell lung cancer patients with activating EGFR mutations (Exon19del or L858R) or with the T790M resistance mutation following disease progression on first- or second-generation EGFR TKIs. The aim of this work is to rationalize and understand how osimertinib achieves mutant EGFR selectivity over the wild-type (WT) by evaluating its kinetic mechanism of action. In doing so, we developed methodologies combining steady-state and pre-steady-state kinetics to determine the covalent inactivation rates (kinact) and reversible binding affinities (Ki) for osimertinib against WT, L858R, and L858R/T790M EGFR and compared these data to the inhibition kinetics of earlier generations of EGFR TKIs. The kinact/KI values indicate osimertinib inactivates L858R and L858R/T790M with 20- and 50-fold higher overall efficiencies, respectively, compared to that for WT. The Ki and kinact values reveal that osimertinib binds 3-fold tighter to and reacts 3-fold faster with L858R than WT EGFR and binds 17-fold tighter to and reacts 3-fold faster with L858R/T790M than with the WT EGFR. We conclude that osimertinib overcomes the T790M mutation through improved affinities from stronger hydrophobic interactions with Met790 versus Thr790 and an improved rate of covalent bond formation via better positioning of the acrylamide warhead, while osimertinib targets the L858R mutation through better affinities and reactivities with the mutant in the context of differential binding affinities of the competing substrate ATP. This work highlights the importance of optimizing both reversible drug-target interactions and inactivation rates for covalent inhibitors to achieve selectivity in targeting mutant EGFRs." @default.
• W3012576274 created "2020-03-27" @default.
• W3012576274 creator A5006496354 @default.
• W3012576274 creator A5038751205 @default.
• W3012576274 creator A5083925014 @default.
• W3012576274 creator A5084047203 @default.
• W3012576274 date "2020-03-24" @default.
• W3012576274 modified "2023-10-02" @default.
• W3012576274 title "Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies" @default.
• W3012576274 cites W1940083515 @default.
• W3012576274 cites W1963826141 @default.
• W3012576274 cites W1964217341 @default.
• W3012576274 cites W1968656389 @default.
• W3012576274 cites W1989331708 @default.
• W3012576274 cites W1998885514 @default.
• W3012576274 cites W2002937040 @default.
• W3012576274 cites W2003867647 @default.
• W3012576274 cites W2004211026 @default.
• W3012576274 cites W2007649418 @default.
• W3012576274 cites W2011513069 @default.
• W3012576274 cites W2016408686 @default.
• W3012576274 cites W2019012381 @default.
• W3012576274 cites W2028689547 @default.
• W3012576274 cites W2035495099 @default.
• W3012576274 cites W2043696829 @default.
• W3012576274 cites W2063391304 @default.
• W3012576274 cites W2077451485 @default.
• W3012576274 cites W2088540000 @default.
• W3012576274 cites W2090029719 @default.
• W3012576274 cites W2111109297 @default.
• W3012576274 cites W2112098753 @default.
• W3012576274 cites W2131964519 @default.
• W3012576274 cites W2133963438 @default.
• W3012576274 cites W2136088472 @default.
• W3012576274 cites W2136343696 @default.
• W3012576274 cites W2138536086 @default.
• W3012576274 cites W2138851777 @default.
• W3012576274 cites W2149654081 @default.
• W3012576274 cites W2159013299 @default.
• W3012576274 cites W2416240773 @default.
• W3012576274 cites W2527718275 @default.
• W3012576274 cites W2560717039 @default.
• W3012576274 cites W2587420003 @default.
• W3012576274 cites W2622009965 @default.
• W3012576274 cites W2623565822 @default.
• W3012576274 cites W2751178128 @default.
• W3012576274 cites W2760639821 @default.
• W3012576274 cites W2770828094 @default.
• W3012576274 cites W2801332174 @default.
• W3012576274 cites W2899325153 @default.
• W3012576274 cites W2921774375 @default.
• W3012576274 cites W2936788142 @default.
• W3012576274 cites W2971229303 @default.
• W3012576274 cites W2990041408 @default.
• W3012576274 doi "https://doi.org/10.1021/acs.biochem.0c00104" @default.
• W3012576274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32207968" @default.
• W3012576274 hasPublicationYear "2020" @default.
• W3012576274 type Work @default.
• W3012576274 sameAs 3012576274 @default.
• W3012576274 citedByCount "27" @default.
• W3012576274 countsByYear W30125762742020 @default.
• W3012576274 countsByYear W30125762742021 @default.
• W3012576274 countsByYear W30125762742022 @default.
• W3012576274 countsByYear W30125762742023 @default.
• W3012576274 crossrefType "journal-article" @default.
• W3012576274 hasAuthorship W3012576274A5006496354 @default.
• W3012576274 hasAuthorship W3012576274A5038751205 @default.
• W3012576274 hasAuthorship W3012576274A5083925014 @default.
• W3012576274 hasAuthorship W3012576274A5084047203 @default.
• W3012576274 hasConcept C12554922 @default.
• W3012576274 hasConcept C170493617 @default.
• W3012576274 hasConcept C185592680 @default.
• W3012576274 hasConcept C2777626846 @default.
• W3012576274 hasConcept C2777930144 @default.
• W3012576274 hasConcept C2778087573 @default.
• W3012576274 hasConcept C2779438470 @default.
• W3012576274 hasConcept C2780580887 @default.
• W3012576274 hasConcept C42362537 @default.
• W3012576274 hasConcept C55493867 @default.
• W3012576274 hasConcept C86803240 @default.
• W3012576274 hasConceptScore W3012576274C12554922 @default.
• W3012576274 hasConceptScore W3012576274C170493617 @default.
• W3012576274 hasConceptScore W3012576274C185592680 @default.
• W3012576274 hasConceptScore W3012576274C2777626846 @default.
• W3012576274 hasConceptScore W3012576274C2777930144 @default.
• W3012576274 hasConceptScore W3012576274C2778087573 @default.
• W3012576274 hasConceptScore W3012576274C2779438470 @default.
• W3012576274 hasConceptScore W3012576274C2780580887 @default.
• W3012576274 hasConceptScore W3012576274C42362537 @default.
• W3012576274 hasConceptScore W3012576274C55493867 @default.
• W3012576274 hasConceptScore W3012576274C86803240 @default.
• W3012576274 hasFunder F4320307770 @default.
• W3012576274 hasIssue "14" @default.
• W3012576274 hasLocation W30125762741 @default.
• W3012576274 hasLocation W30125762742 @default.
• W3012576274 hasOpenAccess W3012576274 @default.
• W3012576274 hasPrimaryLocation W30125762741 @default.
• W3012576274 hasRelatedWork W2618442076 @default.

• next